Product Description
specification:
English name Pramipexole dihydrochloride
CAS NO. 104632-25-9
Synonym (s)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride; Pramipexole Hcl; Pramipexole 2HCl; Pramipexole di hcl; (6R)-N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; (6S)-N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride; (6S)-N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrochloride (1:1)
Molecular Weight 247.788
Molecular Formula C10H18ClN3S
introduction :
Pramipexole (Mirapex, Mirapexin, Sifrol) is a dopamine agonist of the non-ergoline class indicated for treating Parkinson''s disease (PD)and restless legs syndrome (RLS).It is also sometimes used off-label as a treatment for cluster headache and to counteract problems with sexual dysfunction experienced by some users of selective serotonin reuptake inhibitor (SSRI) antidepressants.Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder.It is also being investigated for the treatment of clinical depression and fibromyalgia.
Pramipexole acts as a partial/full agonist at the following receptors:
D2S receptor (Ki = 3.9 nM; IA = 130%)
D2L receptor (Ki = 2.2 nM; IA = 70%)
D3 receptor (Ki = 0.5 nM; IA = 70%)
D4 receptor (Ki = 5.1 nM; IA = 42%)
Pramipexole also possesses low/insignificant affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors.It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors.All sites assayed were done using human tissues.
While pramipexole is used clinically (see below), its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, pramipexole has been used (in combination with D2- and or D3-preferrin
